TY - JOUR
T1 - CarDiac magnEtic Resonance for prophylactic Implantable-cardioVerter defibrillAtor ThErapy in Non-Ischaemic dilated CardioMyopathy
T2 - An international Registry
AU - Guaricci, Andrea Igoren
AU - Masci, Pier Giorgio
AU - Muscogiuri, Giuseppe
AU - Guglielmo, Marco
AU - Baggiano, Andrea
AU - Fusini, Laura
AU - Lorenzoni, Valentina
AU - Martini, Chiara
AU - Andreini, Daniele
AU - Pavon, Anna Giulia
AU - Aquaro, Giovanni D.
AU - Barison, Andrea
AU - Todiere, Giancarlo
AU - Rabbat, Mark G.
AU - Tat, Emily
AU - Raineri, Claudia
AU - Valentini, Adele
AU - Varga-Szemes, Akos
AU - Schoepf, U. Joseph
AU - De Cecco, Carlo N.
AU - Bogaert, Jan
AU - Dobrovie, Monica
AU - Symons, Rolf
AU - Focardi, Marta
AU - Gismondi, Annalaura
AU - Lozano-Torres, Jordi
AU - Rodriguez-Palomares, Josè F.
AU - Lanzillo, Chiara
AU - Di Roma, Mauro
AU - Moro, Claudio
AU - Di Giovine, Gabriella
AU - Margonato, Davide
AU - De Lazzari, Manuel
AU - Perazzolo Marra, Martina
AU - Nese, Alberto
AU - Casavecchia, Grazia
AU - Gravina, Matteo
AU - Marzo, Francesca
AU - Carigi, Samuela
AU - Pica, Silvia
AU - Lombardi, Massimo
AU - Censi, Stefano
AU - Squeri, Angelo
AU - Palumbo, Alessandro
AU - Gaibazzi, Nicola
AU - Camastra, Giovanni
AU - Sbarbati, Stefano
AU - Pedrotti, Patrizia
AU - Masi, Ambra
AU - Carrabba, Nazario
N1 - Publisher Copyright:
© 2021 Published on behalf of the European Society of Cardiology. All rights reserved.
PY - 2021/7/1
Y1 - 2021/7/1
N2 - Aims: The aim of this registry was to evaluate the additional prognostic value of a composite cardiac magnetic resonance (CMR)-based risk score over standard-of-care (SOC) evaluation in a large cohort of consecutive unselected non-ischaemic cardiomyopathy (NICM) patients. Methods and results: In the DERIVATE registry (www.clinicaltrials.gov/registration: RCT#NCT03352648), 1000 (derivation cohort) and 508 (validation cohort) NICM patients with chronic heart failure (HF) and left ventricular ejection fraction <50% were included. All-cause mortality and major adverse arrhythmic cardiac events (MAACE) were the primary and secondary endpoints, respectively. During a median follow-up of 959 days, all-cause mortality and MAACE occurred in 72 (7%) and 93 (9%) patients, respectively. Age and >3 segments with midwall fibrosis on late gadolinium enhancement (LGE) were the only independent predictors of all-cause mortality (HR: 1.036, 95% CI: 1.0117-1.056, P < 0.001 and HR: 2.077, 95% CI: 1.211-3.562, P = 0.008, respectively). For MAACE, the independent predictors were male gender, left ventricular end-diastolic volume index by CMR (CMR-LVEDVi), and >3 segments with midwall fibrosis on LGE (HR: 2.131, 95% CI: 1.231-3.690, P = 0.007; HR: 3.161, 95% CI: 1.750-5.709, P < 0.001; and HR: 1.693, 95% CI: 1.084-2.644, P = 0.021, respectively). A composite clinical and CMR-based risk score provided a net reclassification improvement of 63.7% (P < 0.001) for MAACE occurrence when added to the model based on SOC evaluation. These findings were confirmed in the validation cohort. Conclusion: In a large multicentre, multivendor cohort registry reflecting daily clinical practice in NICM work-up, a composite clinical and CMR-based risk score provides incremental prognostic value beyond SOC evaluation, which may have impact on the indication of implantable cardioverter-defibrillator implantation.
AB - Aims: The aim of this registry was to evaluate the additional prognostic value of a composite cardiac magnetic resonance (CMR)-based risk score over standard-of-care (SOC) evaluation in a large cohort of consecutive unselected non-ischaemic cardiomyopathy (NICM) patients. Methods and results: In the DERIVATE registry (www.clinicaltrials.gov/registration: RCT#NCT03352648), 1000 (derivation cohort) and 508 (validation cohort) NICM patients with chronic heart failure (HF) and left ventricular ejection fraction <50% were included. All-cause mortality and major adverse arrhythmic cardiac events (MAACE) were the primary and secondary endpoints, respectively. During a median follow-up of 959 days, all-cause mortality and MAACE occurred in 72 (7%) and 93 (9%) patients, respectively. Age and >3 segments with midwall fibrosis on late gadolinium enhancement (LGE) were the only independent predictors of all-cause mortality (HR: 1.036, 95% CI: 1.0117-1.056, P < 0.001 and HR: 2.077, 95% CI: 1.211-3.562, P = 0.008, respectively). For MAACE, the independent predictors were male gender, left ventricular end-diastolic volume index by CMR (CMR-LVEDVi), and >3 segments with midwall fibrosis on LGE (HR: 2.131, 95% CI: 1.231-3.690, P = 0.007; HR: 3.161, 95% CI: 1.750-5.709, P < 0.001; and HR: 1.693, 95% CI: 1.084-2.644, P = 0.021, respectively). A composite clinical and CMR-based risk score provided a net reclassification improvement of 63.7% (P < 0.001) for MAACE occurrence when added to the model based on SOC evaluation. These findings were confirmed in the validation cohort. Conclusion: In a large multicentre, multivendor cohort registry reflecting daily clinical practice in NICM work-up, a composite clinical and CMR-based risk score provides incremental prognostic value beyond SOC evaluation, which may have impact on the indication of implantable cardioverter-defibrillator implantation.
KW - Cardiac magnetic resonance
KW - Heart failure
KW - Implantable cardioverter-defibrillator
KW - Non-ischaemic dilated cardiomyopathy
KW - Primary prevention
UR - http://www.scopus.com/inward/record.url?scp=85112125923&partnerID=8YFLogxK
U2 - 10.1093/europace/euaa401
DO - 10.1093/europace/euaa401
M3 - Article
C2 - 33792661
AN - SCOPUS:85112125923
SN - 1099-5129
VL - 23
SP - 1072
EP - 1083
JO - Europace
JF - Europace
IS - 7
ER -